

GENOME THERAPEUTICS CORP  
Form DEFA14A  
January 16, 2004

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the**  
**Securities Exchange Act of 1934**

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to Section 240.14a-11(c) or Section 240.14a-12

**GENOME THERAPEUTICS CORP.**

---

(Name of Registrant as Specified In Its Charter)

---

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (check the appropriate box):

Edgar Filing: GENOME THERAPEUTICS CORP - Form DEFA14A

- x No fee required.
- .. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  - 1) Title of each class of securities to which transaction applies:
  - 2) Aggregate number of securities to which transaction applies:
  - 3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11:
  - 4) Proposed maximum aggregate value of transaction:
  - 5) Total fee paid:
  
- .. Fee paid previously with preliminary materials:
  
- .. Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  - 1) Amount previously paid:
  - 2) Form, Schedule or Registration Statement No.:
  - 3) Filing Party:
  - 4) Date Filed:

100 Beaver Street

Waltham, MA 02453

781-398-2300

[www.genomecorp.com](http://www.genomecorp.com)

January 16, 2004

---

### IMPORTANT REMINDER

---

Dear Fellow Stockholder:

Our Special Meeting of Stockholders is fast approaching and according to our latest records, your vote for this meeting **has not** been received.

At Genome Therapeutics, we have always been proud of the fact that our shareholder base is primarily made up of individual investors like you. Your vote is very important to us regardless of the number of shares you own. Please vote in **FAVOR** of all proposals today.

You can vote using any of the methods listed below. Voting is fast, easy and at no-cost to you.

Using a touch-tone telephone, call the toll-free number located on the enclosed Voting Instruction Form. You will be prompted for the 12-digit control number located in the gray shaded box on the form and given simple instructions on casting your vote.

Vote over the internet at [www.proxyvote.com](http://www.proxyvote.com) using the 12-digit control number located on the Voting Instruction Form to cast your vote quickly and conveniently.

Edgar Filing: GENOME THERAPEUTICS CORP - Form DEFA14A

Sign, date and mail the Voting Instruction Form in the enclosed postage-paid envelope.

If you have any questions regarding how to vote your shares, please do not hesitate to contact **The Altman Group Inc.**, our proxy solicitor toll free at **1-800-217-0538**. Please feel free to contact our Investor Relations group at 781-398-2300 with any other questions.

Thank you in advance for your support.

Sincerely,

Steven M. Rauscher

Chairman, President and Chief Executive Officer

Genome Therapeutics

---

**IF YOU HAVE RECENTLY VOTED,  
PLEASE ACCEPT OUR THANKS AND DISREGARD THIS REQUEST.**

---